Terziivanov D, Vlahov V, Belovezhdov N, Gerova Z
Clinic of Internal Medicine, Medical Academy, Sofia, Bulgaria.
Eur J Clin Pharmacol. 1988;34(2):125-8. doi: 10.1007/BF00614547.
The antihypertensive effects of the new cardioselective beta-blocker celiprolol and acebutolol have been compared. Thirty patients with arterial hypertension WHO Grade I-II were treated in a double-blind fashion with celiprolol or acebutolol. Before starting the treatment and on Days 15 and 29, before the morning dose, blood samples were taken for measurement of the plasma level of celiprolol. At the same times physical examinations, and clinical and urine chemistry analyses were performed. At the 99% probability level both drugs had significantly lowered the systolic and diastolic blood pressures to normal values at the end of the second and fourth weeks. There was no significant difference between their antihypertensive efficacy. The decrease in diastolic blood pressure at the end of the second week was significantly correlated with the reciprocal of the plasma celiprolol concentration at steady-state at the end of the dosage interval.
对新型心脏选择性β受体阻滞剂塞利洛尔和醋丁洛尔的降压效果进行了比较。30例世界卫生组织I-II级高血压患者以双盲方式接受塞利洛尔或醋丁洛尔治疗。在开始治疗前以及第15天和第29天，在晨服药物前采集血样以测定塞利洛尔的血浆水平。同时进行体格检查、临床和尿液化学分析。在99%的概率水平下，两种药物在第二周和第四周结束时均已将收缩压和舒张压显著降至正常水平。它们的降压效果之间没有显著差异。第二周结束时舒张压的下降与给药间隔结束时稳态血浆塞利洛尔浓度的倒数显著相关。
